ARTICLE | Clinical News

Cubicin daptomycin: Phase II data

July 26, 2010 7:00 AM UTC

In an open-label Phase II safety trial in 74 patients, once-daily 6 and 8 mg doses of IV Cubicin for about 6 weeks following surgery to remove an infected prosthetic joint were safe and led to a simil...